Financial Performance - The company's operating revenue for Q3 2025 was ¥153,893,261.65, representing a year-on-year increase of 3.63%[5] - Net profit attributable to shareholders for Q3 2025 reached ¥20,049,842.08, a significant increase of 143.28% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,330,451.32, reflecting a decrease of 62.39% year-on-year[5] - Total operating revenue for the period was RMB 458,752,567.68, a decrease of 15.1% compared to RMB 540,562,431.05 in the previous period[17] - The company's operating profit for the current period is 162,030,693.89, compared to a loss of 32,315,344.24 in the previous period[18] - Net profit attributable to shareholders of the parent company is 141,098,044.78, a significant recovery from a loss of 16,735,581.13 in the previous period[19] - Basic and diluted earnings per share for the current period are both 0.1373, compared to -0.0163 in the previous period[19] Assets and Liabilities - The company's total assets at the end of Q3 2025 amounted to ¥6,028,688,138.33, an increase of 0.83% from the end of the previous year[5] - Current assets totaled RMB 2,586,400,343.39, an increase of 3.9% from RMB 2,488,838,965.65 at the beginning of the period[15] - Inventory increased significantly to RMB 394,807,069.61, up 60.2% from RMB 246,333,789.57[15] - Non-current assets totaled RMB 3,442,287,794.94, a decrease of 1.4% from RMB 3,490,180,353.09[15] - Total assets reached RMB 6,028,688,138.33, an increase from RMB 5,979,019,318.74 at the beginning of the period[16] - Total liabilities decreased to RMB 327,956,298.26, down 17.6% from RMB 398,371,079.36[16] - Shareholders' equity increased to RMB 5,700,731,840.07, up from RMB 5,580,648,239.38[16] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥5,831,738.30, a decline of 104.56% compared to the same period last year[5] - Total cash inflow from operating activities is 1,166,739,406.02, up from 647,132,663.44 in the previous period[22] - The net cash flow from operating activities is -5,831,738.30, a decline from a positive cash flow of 127,831,479.42 in the previous period[22] - Investment activities generated a net cash flow of -10,472,195.04, an improvement from -90,221,695.76 in the previous period[22] - The company reported a cash and cash equivalents balance of 363,027,327.07 at the end of the period, down from 423,550,721.97 at the end of the previous period[22] - Cash and cash equivalents decreased to RMB 383,945,973.08 from RMB 411,958,243.66, a decline of 6.8%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 54,779[10] - The largest shareholder, Xu Mingbo, holds 22.62% of the shares, totaling 232,406,307 shares[11] Expenses - The company incurred research and development expenses of 75,104,850.67, a decrease from 98,929,930.35 in the previous period[18] - Sales expenses decreased to 73,477,652.02 from 91,222,553.23 in the previous period[18] - The company experienced a tax expense of 18,229,121.33, compared to a tax benefit of -19,420,932.88 in the previous period[18] Fair Value Changes - The company recognized a fair value change gain of ¥1.28 billion in Q3 2025, a year-on-year increase of 204.93%[9] Business Operations - The company has expanded its product trade business, which has led to increased cash outflows for purchasing goods[9]

Core Insights - The NMN concept index rose by 0.95%, ranking 10th among concept sectors, with 18 stocks increasing in value, led by Te Yi Pharmaceutical, which hit the daily limit, and other notable gainers including Su Yan Jing Shen, Zhong Sheng Pharmaceutical, and Shuanglu Pharmaceutical, which rose by 5.93%, 5.22%, and 4.42% respectively [1][2] Market Performance - The NMN concept sector saw a net inflow of 181 million yuan from main funds, with 13 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow. Te Yi Pharmaceutical topped the list with a net inflow of 215 million yuan, followed by Zhong Sheng Pharmaceutical, De Zhan Health, and Shuanglu Pharmaceutical with net inflows of 51.31 million yuan, 35.94 million yuan, and 14.18 million yuan respectively [2][3] Fund Flow Ratios - Te Yi Pharmaceutical, Yaben Chemical, and De Zhan Health had the highest net inflow ratios, with rates of 17.90%, 11.09%, and 9.59% respectively [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002038 证券简称：双鹭药业 公告编号：2025-031 北京双鹭药业股份有限公司关于参股公司轩竹 生物科技股份有限公司拟在香港联交所主板挂牌上市的公告 特此公告。 北京双鹭药业股份有限公司董事会 二〇二五年十月十四日 一、参股公司上市情况概述 北京双鹭药业股份有限公司（以下简称"公司"）参股公司轩竹生物科技股份有限公司（以下简称"轩竹 生物"）预计于2025年10月15日正式在联交所挂牌上市，股份代号为02575.HK。根据轩竹生物全球发售 招股书之披露，其本次全球发售6733.35万股，发售价格为每股11.60港元。轩竹生物在香港上市的详细 内容可在香港联交所网站（www.hkexnews.hk）查阅。 二、公司持股情况 轩竹生物本次发售完成后，本公司持有的其股份总数为178.08万股，预计占其发行后总股份数的 0.34%，本公司持有的轩竹生物股份的禁售期为轩竹生物上市后12个月。 三、对公司的影响 根据《企业会计准则》相关规定，公司对所持轩竹生物的股权划分为"以公允价值计量且其变动计入当 期损益的金融资产"，并列报在"其他非流动金融资产"。 ...

Group 1: Financial Performance - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 45% to 65% due to reforms and improved investment returns [2] - Feirongda anticipates a net profit of 275 million to 300 million yuan for the first three quarters of 2025, reflecting a growth of 110.80% to 129.96% driven by increased R&D in AI and cooling technologies [2] - Lingyi Zhizao forecasts a net profit of 1.890 billion to 2.120 billion yuan for the first three quarters of 2025, marking a growth of 34.10% to 50.42% attributed to new product launches and increased overseas revenue [5] - Yilake Co. expects a net profit of 4.300 billion to 4.700 billion yuan for the first three quarters of 2025, with a significant increase of 36.89% to 49.62% driven by rising potassium chloride prices [6] - Bojun Technology projects a net profit increase of 50% to 80% for the first three quarters of 2025 [9] Group 2: Regulatory and Corporate Actions - Fudan Zhangjiang's application for the drug Obeticholic Acid for primary biliary cholangitis was not approved by the National Medical Products Administration, with a total R&D investment of approximately 125 million yuan [3] - Northern Rare Earth received a warning letter from the Inner Mongolia Securities Regulatory Bureau for failing to disclose non-operating fund occupation by an affiliate, totaling 8.9485 million yuan [7] - Tianji Co. announced that its major shareholders reduced their holdings by 2.9996% and have terminated their reduction plan ahead of schedule [8] Group 3: Market Trends and Developments - The demand for AI server cooling solutions and related materials has increased, contributing to Feirongda's revenue growth [2] - The overall market for potassium chloride has seen price increases, positively impacting Yilake Co.'s profitability [6] - The consumer electronics market is recovering, leading to increased demand for thermal management materials, benefiting Feirongda's market share [2]

Core Viewpoint - Shuanglu Pharmaceutical's associate company, Xuan Zhu Bio, is expected to officially list on the Hong Kong Stock Exchange on October 15, 2025, with a global offering of 67.335 million shares priced at HKD 11.60 per share [1] Summary by Relevant Sections - **Company Holdings** - Shuanglu Pharmaceutical holds a total of 1.7808 million shares in Xuan Zhu Bio, which is expected to represent 0.34% of the total shares post-issuance [1] - **Lock-up Period** - The lock-up period for Shuanglu Pharmaceutical's shares in Xuan Zhu Bio will last for 12 months following the company's listing [1]

Core Viewpoint - Shuanglu Pharmaceutical (002038.SZ) announced that its associate company, Xuan Zhu Bio (02575), is expected to officially list on the Hong Kong Stock Exchange on October 15, 2025, with a global offering of 67.335 million shares priced at HKD 11.60 per share [1] Company Summary - Shuanglu Pharmaceutical holds a total of 1.7808 million shares in Xuan Zhu Bio, which is expected to represent 0.34% of the total shares post-issuance [1] - The lock-up period for the shares held by Shuanglu Pharmaceutical will last for 12 months following the listing of Xuan Zhu Bio [1]

Core Viewpoint - The company Shuanglu Pharmaceutical (002038) announced that its associate company, XuanZhu Biotechnology Co., Ltd., is expected to officially list on the main board of the Hong Kong Stock Exchange on October 15, 2025 [1] Summary by Relevant Categories - **Company Information** - Shuanglu Pharmaceutical will hold a total of 1.7808 million shares in XuanZhu Biotechnology after the completion of the offering, which is expected to account for 0.34% of the total shares post-issuance [1]

格隆汇10月13日丨双鹭药业(002038.SZ)公布，参股公司轩竹生物科技股份有限公司（简称"轩竹生物"） 预计于2025年10月15日正式在联交所挂牌上市，股份代号为02575.HK。根据轩竹生物全球发售招股书 之披露，其本次全球发售6733.35万股，发售价格为每股11.60港元。轩竹生物本次发售完成后，本公司 持有的其股份总数为178.08万股，预计占其发行后总股份数的0.34%，本公司持有的轩竹生物股份的禁 售期为轩竹生物上市后12个月。 ...

一、参股公司上市情况概述 北京双鹭药业股份有限公司（以下简称"公司"）参股公司轩竹生物科技股份有限公司 （以下简称"轩竹生物"）预计于 2025 年 10 月 15 日正式在联交所挂牌上市，股份代号为 02575.HK。根据轩竹生物全球发售招股书之披露，其本次全球发售 6733.35 万股，发售价格 为每股 11.60 港元。轩竹生物在香港上市的详细内容可在香港联交所网站（www.hkexnews.hk） 查阅。 二、公司持股情况 轩竹生物本次发售完成后，本公司持有的其股份总数为 178.08 万股，预计占其发行后 总股份数的 0.34%，本公司持有的轩竹生物股份的禁售期为轩竹生物上市后 12 个月。 证券代码：002038 证券简称：双鹭药业 公告编号：2025-031 北京双鹭药业股份有限公司关于参股公司轩竹生物 科技股份有限公司拟在香港联交所主板挂牌上市的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 根据《企业会计准则》相关规定，公司对所持轩竹生物的股权划分为"以公允价值计量 且其变动计入当期损益的金融资产"，并列报在"其他非流动金融资产"。轩竹 ...

格隆汇10月13日｜双鹭药业公告称，公司参股公司轩竹生物预计于2025年10月15日正式在联交所挂牌上 市，股份代号为02575.HK。本次全球发售6733.35万股，发售价格为每股11.60港元。双鹭药业预计持有 其发行后总股份数的0.34%，禁售期为上市后12个月。 ...